UTAH MEDICAL PRODUCTS, INC. (UTMD) Gross Margin
- Gross margin · 12 months: Value 57.90%; Formula and calculation Gross profit / revenue. Period ending 2026-06-30..
Gross margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Gross margin · 12 months | 57.90% | Gross profit / revenue. Period ending 2026-06-30. $20.91M ÷ $36.11M × 100 ≈ 57.90% |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Gross profit | 20.91M USD | Gross Profit |
| Revenue | 36.11M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | 15.20M USD | Cost of Goods and Services Sold |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Gross profit (USD) | Revenue (USD) | Cost of products and services (USD) | Gross margin |
|---|---|---|---|---|
| 2026-06-30 | $20.91M | $36.11M | $15.20M | 57.90% |
| 2026-03-31 | $21.75M | $37.53M | $15.79M | 57.94% |
| 2025-12-31 | $22.00M | $38.52M | $16.52M | 57.12% |
| 2025-09-30 | $22.06M | $38.63M | $16.57M | 57.10% |
| 2025-06-30 | $22.26M | $38.83M | $16.57M | 57.33% |
| 2025-03-31 | $22.91M | $39.27M | $16.36M | 58.35% |
| 2024-12-31 | $24.14M | $40.90M | $16.76M | 59.03% |
| 2024-09-30 | $25.92M | $44.08M | $18.16M | 58.80% |
| 2024-06-30 | $27.48M | $46.58M | $19.10M | 58.99% |
| 2024-03-31 | $28.96M | $49.04M | $20.08M | 59.05% |
| 2023-12-31 | $30.04M | $50.22M | $20.19M | 59.81% |
| 2023-09-30 | $31.27M | $51.47M | $20.20M | 60.75% |
| 2023-06-30 | $32.09M | $51.91M | $19.82M | 61.82% |
| 2023-03-31 | $32.51M | $52.48M | $19.97M | 61.94% |
| 2022-12-31 | $32.20M | $52.28M | $20.09M | 61.58% |
| 2022-09-30 | $31.98M | $51.62M | $19.64M | 61.96% |
| 2022-06-30 | $31.87M | $51.24M | $19.37M | 62.20% |
| 2022-03-31 | $31.50M | $50.41M | $18.91M | 62.49% |
| 2021-12-31 | $30.92M | $49.05M | $18.14M | 63.03% |
| 2021-09-30 | $30.07M | $48.15M | $18.08M | 62.45% |
| 2021-06-30 | $28.49M | $46.06M | $17.56M | 61.87% |
| 2021-03-31 | $25.66M | $42.24M | $16.58M | 60.75% |
| 2020-12-31 | $25.55M | $42.18M | $16.63M | 60.57% |
| 2020-09-30 | $26.10M | $42.00M | $15.90M | 62.14% |
| 2020-06-30 | $26.98M | $44.01M | $17.04M | 61.30% |
| 2020-03-31 | $29.53M | $47.07M | $17.55M | 62.73% |
| 2019-12-31 | $29.47M | $46.90M | $17.44M | 62.82% |
| 2019-09-30 | $27.76M | $44.83M | $17.07M | 61.92% |
| 2019-06-30 | $26.67M | $42.73M | $16.05M | 62.43% |
| 2019-03-31 | $26.16M | $41.84M | $15.69M | 62.51% |
| 2018-12-31 | $26.31M | $42.00M | $15.69M | 62.64% |
| 2018-09-30 | $26.67M | $42.44M | (m) | 62.84% |
| 2018-06-30 | $26.87M | $42.18M | (m) | 63.71% |
| 2018-03-31 | $26.78M | $42.04M | (m) | 63.70% |
| 2017-12-31 | $26.39M | $41.41M | (m) | 63.73% |
| 2017-09-30 | $25.36M | $40.06M | (m) | 63.31% |
| 2017-06-30 | $24.64M | $39.59M | (m) | 62.24% |
| 2017-03-31 | $24.00M | $39.26M | (m) | 61.14% |
| 2016-12-31 | $23.69M | $39.30M | (m) | 60.28% |
| 2016-09-30 | $24.14M | $40.03M | (m) | 60.32% |
| 2016-06-30 | $24.45M | $40.32M | (m) | 60.64% |
| 2016-03-31 | $24.30M | $40.23M | (m) | 60.40% |
| 2015-12-31 | $24.18M | $40.16M | (m) | 60.23% |
| 2015-09-30 | $24.68M | $40.82M | (m) | 60.46% |
| 2015-06-30 | $24.80M | $41.59M | (m) | 59.62% |
| 2015-03-31 | $25.05M | $41.68M | (m) | 60.08% |
| 2014-12-31 | $24.98M | $41.28M | (m) | 60.52% |
| 2014-09-30 | $24.59M | $41.12M | (m) | 59.80% |
| 2014-06-30 | $24.34M | $40.44M | (m) | 60.20% |
| 2014-03-31 | $24.04M | $39.95M | (m) | 60.19% |
| 2013-12-31 | $24.27M | $40.49M | (m) | 59.94% |
| 2013-09-30 | $24.30M | $40.24M | (m) | 60.39% |
| 2013-06-30 | $24.83M | $40.70M | (m) | 61.00% |
| 2013-03-31 | $24.85M | $40.72M | (m) | 61.03% |
| 2012-12-31 | $25.31M | $41.55M | (m) | 60.90% |
| 2012-09-30 | $25.20M | $41.63M | (m) | 60.54% |
| 2012-06-30 | $25.24M | $41.92M | (m) | 60.21% |
| 2012-03-31 | $25.43M | $42.27M | (m) | 60.15% |
| 2011-12-31 | $22.40M | $37.86M | (m) | 59.17% |
| 2011-09-30 | (m) | (m) | (m) | (m) |
| 2011-06-30 | (m) | (m) | (m) | (m) |
| 2011-03-31 | (m) | (m) | (m) | (m) |
| 2010-12-31 | $13.21M | $25.12M | (m) | 52.58% |
| 2010-09-30 | (m) | (m) | (m) | (m) |
| 2010-06-30 | (m) | (m) | (m) | (m) |
| 2009-12-31 | $13.79M | $25.92M | (m) | 53.21% |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PRO DEX INC (PDEX) | United States | $0.234B | 13.64 |
| InfuSystem Holdings, Inc (INFU) | United States | $0.253B | 22.52 |
| Neuronetics, Inc. (STIM) | United States | $0.216B | -3.25 |
| Profound Medical Corp. (PROF) | $0.206B | -7.37 | |
| Anika Therapeutics, Inc. (ANIK) | United States | $0.272B | -51.71 |
| ORASURE TECHNOLOGIES INC (OSUR) | United States | $0.272B | -6.26 |
| Cytosorbents Corp (CTSO) | United States | $0.274B | -1.29 |
| TriSalus Life Sciences, Inc. (TLSI) | United States | $0.283B | -9.92 |
| Mobia Medical, Inc. (MOBI) | United States | $0.293B | |
| TREACE MEDICAL CONCEPTS, INC. (TMCI) | United States | $0.297B | -4.32 |